Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436985 | 0.66 | ALDH1A1 (0.49) | ALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL23009678 | 0.63 | FKBP5 (0.34) | ALDH1A1MAPK1 | |
| SCHEMBL23009557 | 0.63 | FKBP5 (0.34) | ALDH1A1MAPK1 | |
| SCHEMBL23009556 | 0.63 | FKBP5 (0.34) | ALDH1A1MAPK1 | |
| SCHEMBL17902016 | 0.62 | ALDH1A1 (0.34) | ALDH1A1GAA | |
| SCHEMBL23009660 | 0.62 | GRIN1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL23009680 | 0.62 | GRIN1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL24112195 | 0.62 | GRIN1 (0.34) | ALDH1A1MAPK1 | |
| SCHEMBL21225681 | 0.61 | FKBP5 (0.36) | — | |
| SCHEMBL17901983 | 0.60 | ALDH1A1 (0.35) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | ALDH1A1 2115/4885GAA 2500/4885HPGD 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.